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Abstract
Background: Currently, there is clear evidence that apoptosis plays an important role in the development and
progression of tumors. One of the best characterized apoptosis triggering systems is the CD95/Fas/APO-1 pathway;
previous reports have demonstrated high levels of soluble CD95 (sCD95) in serum of patients with some types of cancer.
Cervical cancer is the second most common cancer among women worldwide. As a first step in an attempt to design a
minimally invasive test to predict the risk of developing cervical cancer in patients with precancerous lesions, we used a
simple assay based on the capacity of human serum to induce apoptosis in Jurkat cells. We evaluated the relationship
between sCD95 levels and the ability to induce apoptosis in Jurkat cells in cervical cancer patients and controls.
Methods: Jurkat cells were exposed to serum from 63 women (20 healthy volunteers, 21 with cervical intraepithelial
neoplasia grade I [CIN 1] and 22 with cervical-uterine carcinoma). The apoptotic rate was measured by flow cytometry
using Annexin-V-Fluos and Propidium Iodide as markers. Serum levels of sCD95 and soluble CD95 ligand (sCD95L) were
measured by ELISA kits.
Results: We found that serum from almost all healthy women induced apoptosis in Jurkat cells, while only fifty percent
of the sera from women with CIN 1 induced cell death in Jurkat cells. Interestingly, only one serum sample from a patient
with cervical-uterine cancer was able to induce apoptosis, the rest of the sera protected Jurkat cells from this killing. We
were able to demonstrate that elimination of Jurkat cells was mediated by the CD95/Fas/Apo-1 apoptotic pathway.
Furthermore, the serum levels of sCD95 measured by ELISA were significantly higher in women with cervical cancer.
Conclusion: Our results demonstrate that there is a strong correlation between low levels of sCD95 in serum of
normal women and higher apoptosis induction in Jurkat cells. We suggest that an analysis of the apoptotic rate induced
by serum in Jurkat cells and the levels of sCD95 in serum could be helpful during the prognosis and treatment of women
detected with precancerous lesions or cervical cancer.
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Background
A balance between apoptosis and cell proliferation are
crucial features for the maintenance of homeostasis in
multicellular organisms [1]. In malignant cells, apoptotic
pathways are often disturbed, leading to uncontrollable
growth and to resistance to anti-tumor treatment [2,3]. It
is now well established that apoptosis plays an important
role in the regulation of tumor progression [4,5]. Diverse
molecular mechanisms, such as overexpression of anti-
apoptotic proteins, inactivation of death receptors and
mutations or epigenetic regulation of tumor suppressor
genes, have been implicated in the failure of apoptosis in
tumor cells [6-8].
Anti-apoptotic factors act directly by interfering with
death receptor activation or indirectly by triggering an
intracellular response that perturbs the apoptotic signal-
ing cascades. One of the best characterized systems that
triggers apoptosis is the CD95/Fas/APO-1 pathway [9-11].
CD95 is a member of the tumor necrosis factor receptor
superfamily [12,13] that induces apoptosis in a variety of
cell types. It is characterized by an intracellular domain,
the "death domain". After CD95 ligand (CD95L) binding,
the death domain attracts the intracellular adaptor protein
FADD [14], which in turn recruits the "initiator" procas-
pase-8 and procaspase-10, forming a protein complex
called DISC (death-inducing signaling complex) [15,16].
After autocatalytic activation of procaspase-8 at the DISC,
active initiator caspase-8 can either directly or indirectly
(via the mitochondrial pathway) activate downstream
effector caspases (caspase-3, -6 and -7), leading to the
cleavage of cellular proteins and subsequent apoptosis
[9].
CD95 consists of two isoforms, one of them is anchored
to the cellular membrane (mCD95) and the other one is
present in a soluble form (sCD95). The first contains a
single transmembrane region and induces apoptosis in
normal or tumor cells, whereas the sCD95 lacks the trans-
membrane domain as a result of an alternative splicing
and is thought to block apoptosis by CD95L binding [17].
Previous reports have demonstrated high levels of sCD95
in serum of patients with different malignancies such as
bladder, breast, renal cell, hepatocellular and gynecologi-
cal carcinomas [18-24].
CD95L is a 37 kDa membrane protein belonging to the
TNF family, however, a soluble form is generated by a
metalloproteinase-like protease and it is suggested that
sCD95L prevents the recognition of tumor cells by bind-
ing to and inducing apoptosis in the cytotoxic T-cells [25].
It was reported that serum from healthy individuals does
not contain detectable levels of sCD95L, whereas the pres-
ence of sCD95L has been noted in the serum of patients
with some types of neoplasias [26-28].
Cervical cancer is the second most common cancer among
women worldwide and represents the first cause of cancer
death in developing countries, with an estimated of
493,000 new cases and 274,000 deaths during 2002 [29].
Infection with high-risk human papilloma virus (HPV) is
considered the major etiological factor of premalignant
lesions and cervical cancer [30,31]. Virtually almost 100%
of cervical carcinoma samples have been shown to be pos-
itive for the presence of HPV-DNA [32]. The screening for
cervical cancer and its precursor lesions currently employs
the Pap smear, but this test is subjective and has relatively
low sensitivity. The combination of the Pap test with HPV
molecular detection achieves significant improvements in
sensitivity for the detection of cervical cancer, but the last
technique is not routinely employed due to methodolog-
ical and economical reasons. Alternatively, the use of
p16INK4a has been proposed as a prognostic marker for
progression [33,34]; however, disadvantages of this
method are that it is mainly confined to biopsies and it is
also subjective depending on the pathologist's experience.
At present in developing countries, women with cervical
intraepithelial neoplasia grade 1 are normally maintained
under observation, since almost 60% of these cases revert
spontaneously [35,36]. To predict which of those patients
are at a higher risk for progression to cervical cancer, it is
necessary to look for new simple and low cost comple-
mentary prognostic methods. In the current study we used
a very simple method based on the capacity of human
serum to induce apoptosis in Jurkat cells in an effort to
identify a prognostic marker or method which could assist
in determining or predicting the risk of developing cervi-
cal cancer.
Methods
Patients
The study group consisted of 22 women with clinical and
histopathological diagnosis of squamous cell carcinoma
of the cervix, 21 women with CIN 1 (Cervical Intraepithe-
lial Neoplasia grade 1 – mild dysplasia) and 20 healthy
female volunteers. The age of cancer patients, CIN 1, and
control group ranged from 30 to 83, 22 to 55, and 22 to
46 years, respectively. It is important to mention that
patients included in this study did not receive any prior
treatment (chemotherapy, radiotherapy or surgery). All
patients signed an informed consent form approved by
the Ethical Committee of the Instituto Mexicano del Seg-
uro Social.
Serum samples
Sera from untreated patients with cervical intraepithelial
neoplasias grade 1 and with cervical cancer were obtained
at Centro Médico Nacional de Occidente – IMSS. Control
serum samples were obtained from healthy donors. All
serum samples were obtained from peripheral blood byBMC Cancer 2008, 8:99 http://www.biomedcentral.com/1471-2407/8/99
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venipuncture after centrifugation at 2000 rpm for 15 min-
utes, aliquoted and stored at -70°C until used.
Cell Culture
JURKAT and JURKATR (kindly obtained from Dr. Peter
Krammer, DKFZ-Heidelberg, Germany) were cultured
routinely in RPMI 1640 medium, supplemented with
10% fetal calf serum, 100 U/mL penicillin and 100 μg/mL
streptomycin. All products mentioned before were
obtained from GIBCO™ Invitrogen Corporation. Cultures
were maintained at 37°C in a humidified atmosphere
with 5% CO2. JURKATR is a JURKAT variant resistant to
CD95-mediated apoptosis obtained after continuous
exposure to agonistic Apo-1 antibody [37].
Exposure of sera to Jurkat cells and apoptosis detection
To test the rate of apoptosis induced by sera from the dif-
ferent groups, JURKAT or JURKATR cells were seeded at a
density of 2.5 × 105 cells per well in 1 mL RPMI medium
in 6-well plates. Afterwards, 0.5 mL of serum from the dif-
ferent women was added. After 3 days of incubation, cell
death was measured by flow cytometry using propidium
iodide (Cat. P4864, Sigma-Aldrich, Germany) and
Annexin-V-Fluos (Cat. 1828681, Roche Applied Science,
Germany) as recommended by the manufacturers. For
each sample, 10,000 events were analyzed in an Epics XL
– MCL™ Flow Cytometer (Beckman Coulter, USA) using
the FL-1 and FL-3 detector filters. Each serum was tested 3
to 5 times in independent experiments.
Induction of apoptosis by CD95L
To corroborate the sensitivity of JURKAT and JURKATR
cells to CD95L-induced apoptosis, 3.5 × 105 cells were
seeded in 6-well plates and exposed to 5 μg/mL anti-Fas-
human, activating- clone CH11 (Cat. 05-201, Lot. 33574,
Upstate-Millipore Corporation), in a final volume of 1 mL
RPMI medium. After 24 hours of incubation, apoptosis
was measured by flow cytometry using Annexin-V-Fluos
and Propidium Iodide as markers. Flow cytometry was
performed in a FACSAria cytometer using for acquisition
and analysis the FACSDiva software (Becton Dickinson,
USA).
Detection of sCD95 and sCD95L in serum
Serum concentrations of sCD95 and sCD95L were meas-
ured using the Human APO-1/FAS ELISA Kit (Cat.
KHS9502, BioSource International) and the Human sFAS
Ligand ELISA Kit (Cat. KHS9521, BioSource Interna-
tional), according to the manufacturer's specifications.
The ranges of the kits for sCD95 and sCD95L were
0.23–15 ng/mL and 0.72–12.92 ng/mL, respectively. The
sensitivity for APO-1/FAS is <20 pg/mL and for sFAS Lig-
and 0.1 ng/mL.
Statistical analysis
Differences observed in the sensitivity of Jurkat cells to
undergo apoptosis or in the sCD95 levels detected in sera
between healthy controls, CIN 1 and cancer patients were
analyzed using paired samples T-tests. To evaluate the cor-
relation between apoptosis and sCD95 levels, Spearman's
correlation coefficient was calculated. Results were con-
sidered statistically significant when p value was less than
0.05 and are presented as mean ± standard deviation.
Analyses of all data were performed with the SPSS soft-
ware version 12.0 (Chicago, Illinois, USA).
Results
Sera from patients with cervical cancer induce a 
cytoprotective effect that prevents apoptosis in Jurkat 
cells
There is still controversy about the effect exerted by serum
of cancer patients on T-lymphocytes. While there is evi-
dence of T-lymphocyte apoptosis mediated by molecules
contained in serum released by tumor cells [38], the
opposite effect, that is, protection from apoptosis when T-
lymphocytes were exposed to serum from cancer patients,
was also reported [39]. To shed light on this discrepancy
in the context of cervical cancer, we analyzed whether sera
from patients with precancerous lesions or cervical cancer
are able to protect or induce apoptosis in T-cells. For this
purpose, we used Jurkat cells, a T-lymphocyte-derived cell
line, as an apoptosis-sensitive model. This cell line is able
to undergo apoptosis by triggering of the intrinsic and the
extrinsic apoptosis pathways. Jurkat cells were exposed to
serum from patients and healthy women volunteers. After
three days of incubation, the apoptotic rates were meas-
ured. Our cohort was divided into three groups: control
healthy women (Fig. 1a), women with CIN 1 (cervical
intraepithelial neoplasia grade 1) (Fig. 1b), and women
with cervical cancer (Fig. 1c). It is important to mention
that serum from all patients included in this study was
collected before any kind of treatment. As can be seen in
Fig. 1a, sera obtained from healthy women were able to
induce apoptosis in Jurkat cells in the majority of the cases
(the percentages of apoptosis induction ranged from 14.2
to 91.4). Of the 20 analyzed sera, 17 (85%) were able to
induce apoptosis in more than 30% of Jurkat cells. Using
the same methodology, 11 out of 21 (52.4%) sera from
women with precancerous lesions were able to induce
apoptosis in more than 30% of Jurkat cells (Fig. 1b). Inter-
estingly, when we tested sera from women with cervical
cancer (Fig. 1c), only one out of 22 (4.5%) sera analyzed
was able to induce apoptosis in more than 30% of Jurkat
cells. It is important to emphasize that Jurkat cells grown
only in RPMI culture medium were always included in
duplicate as controls in each assay; Jurkat cell death
obtained under these conditions ranged from 3 to 13%
(data not shown). In summary, we observed that sera
from healthy women tend to induce a high rate of apop-BMC Cancer 2008, 8:99 http://www.biomedcentral.com/1471-2407/8/99
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Induction of apoptosis in Jurkat cells by women's sera Figure 1
Induction of apoptosis in Jurkat cells by women's sera. The percentage of apoptosis induction in Jurkat cells was deter-
mined after three days exposure to sera from healthy controls (a), cervical intraepithelial neoplasia grade 1 patients (b) or cer-
vical cancer patients (c). Apoptosis was measured by flow cytometry with Annexin-V-Fluos as a marker for 10,000 events. The 
graphic represents the results obtained from 3 to 5 independent experiments with standard deviation.
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tosis in Jurkat cells, whereas sera from patients with cervi-
cal cancer did not induce this killing. Additionally,
approximately 50% of the sera obtained from precancer-
ous lesions showed, in common with the samples from
cancer patients, a failure to induce apoptosis. This sug-
gests that these patients might be at a higher risk for the
progression to malignant lesions.
Serum from healthy women induced apoptosis in Jurkat 
cells through the CD95/Fas/Apo-1 pathway
As previously mentioned, we used Jurkat cells to measure
apoptosis induction by sera. These cells are responsive to
a variety of apoptotic signals including death receptors
and intrinsic signals. Questions arising from our previous
experiments led us to attempt to elucidate the apoptotic
pathway involved in the killing effect induced by healthy
women's sera. To test the relevance of the CD95 pathway
in this apoptotic process, we used a Jurkat derived CD95
resistant cell line (JurkatR) [37]. First, we corroborated the
CD95 sensitivity of Jurkat and JurkatR cells by incubating
both cell lines with CD95 ligand (CD95L) and measuring
the apoptotic rate after 24 hours by flow cytometry using
Annexin-V-Fluos and Propidium Iodide (PI) as markers.
As can be seen in Fig 2, parental Jurkat cells were highly
sensitive to CD95L exposure (90.6% cell death). As
expected, JurkatR cells were resistant to CD95L-induced
Sensitivity of parental Jurkat and JurkatR cells to CD95L-induced apoptosis Figure 2
Sensitivity of parental Jurkat and JurkatR cells to CD95L-induced apoptosis. Jurkat and JurkatR cells were incubated 
24 hours with CD95L as described in Methods, and the rate of apoptosis was measured by flow cytometry using Annexin-V-
Fluos (x axis) and Propidium Iodide (y axis). Q3 represents living cells and Q2 represents cells undergoing apoptosis. The per-
centages of cells in each quadrant are given. The analysis was performed with the BD FACSDiva software. Control cells are 
untreated cells.
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apoptosis, despite the high concentration of CD95L used
and the long time of incubation. After corroborating the
apoptosis sensitivity, we used this resistant property of
JurkatR cells to investigate the role of the CD95 pathway in
the Jurkat killing induced by sera exposure. We selected
those sera that previously demonstrated an ability to
induce apoptosis in Jurkat cells and incubated them in
parallel with both, Jurkat and JurkatR cells. After 3 days of
incubation, apoptosis was measured by flow cytometry
using Annexin and PI as previously mentioned. As
depicted in Fig. 3, sera that induced apoptosis in Jurkat
cells were unable to do so in JurkatR cells. The apoptotic
rate induced in Jurkat cells ranged from 31.5% to 74.1%,
while apoptosis induced in JurkatR cells was similar to that
observed in control cells grown without serum exposure.
These results strongly suggest an involvement of the CD95
pathway in the killing of Jurkat cells by sera from healthy
women.
sCD95 levels in serum of women with cervical cancer 
correlate with the inhibition of apoptosis observed in 
Jurkat cells
Since it was shown that the CD95 pathway was involved
in the elimination of Jurkat cells, we next analyzed the sol-
uble CD95 receptor (sCD95) levels in serum. In order to
perform this goal, we took advantage of commercially
available kits for quantification of sCD95 protein levels
and analyzed all sera included in this study. sCD95 levels
found in healthy women's sera ranged mostly from 1.0 to
1.8 ng/mL; only one serum sample showed a sCD95 pro-
tein level over 2 ng/mL (Fig. 4a). Nevertheless, serum
from patients with cervical cancer showed higher levels of
sCD95 protein (Fig. 4c), in which the majority ranged
between 2.0 and 4.2 ng/mL and one case showed 5.5 ng/
mL. On the other hand, sera from the CIN 1 group
showed in six cases a variation around 0.4 to 1.6 ng/mL of
sCD95 levels, but the majority was over 1.9 ng/mL (Fig.
4b).
Statistical analysis of the data demonstrated that there is a
strong correlation between high levels of sCD95 in serum
and low apoptosis induction in Jurkat cells, as depicted in
Fig. 5, where the correlation between apoptosis and
sCD95 levels was calculated using the Spearman's correla-
tion test. These results confirm the premise that sCD95
present in serum exerts a protective effect on Jurkat cells
avoiding apoptosis (compare Fig. 1 with Fig. 4).
The rate of apoptosis induction in Jurkat cells and the 
sCD95 levels in serum are statistically significant between 
healthy women and women with cervical cancer
We performed a statistical analysis with our experimental
data employing the SPSS software. T-Test and Levene's
Test for equality of variances were achieved to compare
the percentage of apoptosis induction and the sCD95 lev-
els between different groups. Figure 6 displays in box plot
graphics, the median, interquartile ranges and outliers
from our data. As we can observe, there is a statistical sig-
nificance between data obtained in the control group
compared with data from the cervical cancer group. The
significance was not only in the percentage of apoptosis
induction, but also in the sCD95 levels. However, when
we compared the data obtained from CIN 1 group with
the data of control or cancer groups, we observed a statis-
tical significance only in the percentage of apoptosis
induction between CIN 1 and cancer and in the sCD95
expression between control and CIN 1. These results sug-
gest that the percentage of apoptosis induction in Jurkat
cells and the sCD95 levels present in serum could be
important diagnostic and prognostic tools for precancer-
ous lesions advancing to cervical cancer.
Discussion
Currently, there is clear evidence that apoptosis plays an
important role in the development and progression of
tumors [5,40,41]. Apoptosis is regulated by a variety of
extrinsic and intrinsic signals; one of the best known
apoptosis-inducing pathways is the CD95 receptor-ligand
system [41]. It has been shown that neoplastic cells have
different alterations in cell death-involved proteins; some
of which result in an impairment in the function or
expression of CD95 and its ligand, which have been
implicated in the pathogenesis of malignant diseases
[10,41]. One of these alterations is the increased expres-
sion level of sCD95 found in the serum of patients with
some types of cancer. The biological function of sCD95 is
to bind the soluble or membrane-anchored CD95L; this
binding has been shown to protect cells from CD95-medi-
ated apoptosis and represents one method of evading
immuno surveillance [8,17,42].
Taking advantage of this knowledge, the objective of this
study was to design a minimally invasive test which may
serve to predict the risk of developing cervical cancer.
Based on the apoptosis sensitivity of Jurkat cells and the
sCD95 levels found in serum we were able to identify a
possible test system which, in addition, is inexpensive and
quite robust. This goal was reached, since we observed a
significant correlation between the inhibition of the sera's
capacity to induce apoptosis in Jurkat cells and their
sCD95 levels with the stage of disease. Our data obtained
from 63 women show that the majority of sera from
healthy volunteers can efficiently induce apoptosis in Jur-
kat cells; however, cervical cancer patients' sera induce
only a low percentage of apoptosis; in women with CIN 1
lesions, we observed a 50% tendency to efficiently kill Jur-
kat cells (Fig. 1). Interestingly, more than 50% of the CIN
1 lesions regress spontaneously without treatment
[35,36]. This result is in agreement with the report of
Vejda S., et al., in which they established that plasma from BMC Cancer 2008, 8:99 http://www.biomedcentral.com/1471-2407/8/99
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Elimination of Jurkat cells is dependent on the CD95 pathway Figure 3
Elimination of Jurkat cells is dependent on the CD95 pathway. Jurkat and JurkatR cells were cultured in the presence of 
different sera obtained from control volunteers (C17, C19), women with CIN 1 (D8, D21) and serum from a woman with cer-
vical cancer (O20). After 3 days of incubation at 37°C, the apoptosis induced in each T-cell line was measured by flow cytometry 
with Annexin-V-Fluos as a marker. Control: Jurkat or JurkatR cells grown only with complete RPMI medium. M1 represents the 
percentage of cells undergoing apoptosis. A total of 10,000 events were measured; analyses were performed using the 
WinMDI2.8 software. Histograms are representative of separate experiments performed at least twice per condition.
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sCD95 levels in serum Figure 4
sCD95 levels in serum. Concentrations of soluble CD95 were measured by ELISA assays in sera obtained from healthy con-
trols (a), CIN 1 patients (b), or cervical cancer patients (c). sCD95 expression is shown as ng/mL. The results are expressed as 
average ± SD of three measurements from 2 independent experiments.
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cancer patients mediates protection against apoptosis. In
their work, they induced apoptosis in Jurkat cells by add-
ing anti-CD95 antibody or staurosporine supplemented
with plasma samples from prostate, lung and breast can-
cer patients or from healthy human individuals. They
found that the apoptotic indices of Jurkat cells were signif-
icantly reduced when cells were supplemented with
plasma derived from cancer patients; in contrast, supple-
mentation of medium with plasma from healthy human
individuals resulted in higher apoptotic indices [39].
An additional goal in our study was to determine whether
serum-induced apoptosis in Jurkat cells is specifically
mediated by the CD95 pathway, this objective was met by
using the CD95 resistant JurkatR cell line (Fig. 3); these
cells were resistant to undergo apoptosis after incubation
with different sera that were able to induce apoptosis in
Jurkat cells. Since these results strongly suggested a pivotal
role of CD95 in this process, we decided to measure its
expression in the serum of all patients. Using ELISA
assays, we found that sCD95 levels were elevated in the
sera of women with cervical cancer when compared with
those of healthy control women. Comparing our data
with other malignancies, elevated levels of sCD95 in
serum have been also observed in breast cancer [18,19],
bladder [20] and renal carcinomas [21], advance
melanoma [43], B-cell chronic lymphocytic leukemia (B-
CLL) [44] and also in autoimmune rheumatic diseases
[45]. Concerning gynecological tumors, it has been
reported that serum levels of sCD95 are increased in
women with uterine tumors in comparison with the con-
trol group [23]. In addition, Konno et al., examined the
relationship between sCD95 levels and survival rate in
patients with gynecological malignancies; they observed
that patients diagnosed with cervical carcinoma have a
better survival rate when they have serum sCD95 levels
lowers than 1.5 ng/mL before therapy than those with a
level higher than 1.5 ng/mL [24].
Correlation between apoptosis induction in Jurkat cells and serum levels of sCD95 Figure 5
Correlation between apoptosis induction in Jurkat cells and serum levels of sCD95. The Spearman's correlation 
coefficient was calculated using the SPSS software; a significant but inverted correlation was observed (p = 0.0001, r = -0.522).
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Despite the relevance of sCD95L levels found in serum in
other kind of carcinomas [22,46-48], we determined that
serum levels of sCD95L in women were not relevant as a
biomarker in cervical cancer, since we found undetectable
concentrations of this protein by ELISA assays in all
women analyzed (data not shown). These data are contra-
dictory to the observations reported by Kondera-Anasz, et
al., in which they reported a significant increase of
sCD95L in serum of women with uterine tumor com-
pared to the control group [23]; however, one explanation
to this discrepancy could be the use of different commer-
cially available ELISA kits for the sCD95L detection. Con-
cerning healthy volunteers, our data are in agreement with
reports that have found very low levels of sCD95L in
serum of such controls [23,49].
Looking at the sum of our data, we conclude that the per-
centage of apoptosis induction in Jurkat cells and the
sCD95 levels present in serum of women could be impor-
tant diagnostic and prognostic tools for cervical cancer,
however, a follow-up study for at least 2 years must be
made in order to confirm whether the cervical lesions
found in women that are diagnosed as CIN 1, with high
serum levels of sCD95 and a low capacity to eliminate Jur-
kat cells, progress readily to CIN 2. Additionally, it will be
of interest to determine whether these observations are
specific for cervical cancer or if they are found in other
cancers as well.
Conclusion
In conclusion, our results show an anti-apoptotic effect of
sera derived from patients with cervical cancer. Addition-
ally, we were able to show higher levels of soluble CD95
in serum of women with cancer than in those of healthy
controls. We conclude that the disparate levels observed
in patients with cervical cancer versus control patients
protect Jurkat cells from apoptosis and could be an impor-
tant mechanism for evading the antitumor immune
response. We suggest that an analysis of the apoptotic rate
induced by serum in Jurkat cells and the levels of soluble
CD95 in serum could be helpful during the prognosis and
treatment of women detected with precancerous lesions
or cervical cancer.
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